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14. Characterization of erythromycin resistance in streptococcus pneumoniae in 
a defined suburban area 
I? IANNINI, L. OVITTORE AND L. Ross 
Departments of Medicine and Laboratory Medicine, Danbury Hospital, Danbury, CT, US. A. 
The incidence of penicillin resistant Streptococcus pneumoniae (PRSP) has been increasing in the United States. 
Approximately 50% are also resistant to erythromycin (ERSP). To determine the dynamics of ERSP in our single hospital, 
suburban community, we compared the percentage of resistant isolates found in 1998 and 1999 to the years 1994 through 
1997. Erythromycin non-susceptable S. pneumoniae (ENSSP) were defined as the total of all isolates that were resistant or 
intermediately resistant by NCCLS breakpoints, and were tested for cross resistance to penicillin g (PCN), ceftriaxone (CT), 
and levofloxacin (LEVO). Standard broth microdilution methodology was employed to establish minimal inhibitory 
concentrations (MIC’s). 
ERSP accounted for 15% and ENSSP for 20.4% of strains isolated in 1998-99. High level resistance (>16 mg/ml) was found 
in 46% of ERSP, but only 6.8% of all isolates. Isolates collected from 1994-1997 had only 7% ERSP and no high level 
resistance. 42 isolates collected between 1994 and 1999 that were ENSSP (of which 30 were ERSP) were tested for cross 
resistance. The ERSP strains were resistant to PCN 13%, CT 7% and LEVO 0% and for the total of all ENSSP strains to 60%, 
47% and 0% respectively. Erythromycin intermediately resistant strains were not cross resistant to the other antibiotics but 
were also intermediately susceptible to PCN 33%, CT and LEVO 17%. Overall non-susceptibility for the ENSSP strains was 
PCN 52%, CT and LEVO 5%. 
The incidence of ERSP and ENSSP in our community has increased dramatically in the past two years. Cross reistance is 
greatest to PCN, followed by CT and LEVO. High level erythromycin resistance is a now a serious problem in selecting 
empiric antibiotic therapy for respiratory tract infections in our area. 
15. Prevalence of the synobronchial syndrome among school children with sinusitis 
S. PLJASKK KAMENOV, M. FILIPOVIC* AND B. KAMENOV** 
Health Center, *Institute of Pulmonary Diseases, **University Paediatric Hospital, Nis, Yugoslavia 
Aim: to evaluate prevalence of synobronchial syndrome (SBSy) among school children ill with sinusitis. 
Methods; 100 school children ill with sinusitis age 7-18 years were randomly selected. The questionnaires concerning history 
of signs of sinusitis and chronic respiratory disease were filled in. Diagnoses were confirmed by lung function tests and x-ray 
examination. Criteria used to diagnose SBSy were: evidence of sinusitis, chronic respiratory disease and relationship between 
sinusitis and chronic respiratory disease exacerbation. 
Results: 65 (65%) patients with clinical evidence of chronic respiratory disease and sinusitis were found. 18 (27%) had 
obstructive, 47 (72%) non obstructive lung disease. Relationship between sinusitis and chronic respiratory disease exacerbation 
was seen in 37 (56%) examined school children. 39 (60%) school children were diagnosed as having SBSy. Exacerbation of 
chronic respiratory disease followed exacerbation of sinusitis in 2kO.6 and 5kO.4 days (P<O.O5), obstructive and non- 
obstructive lung disease. 
Conclusions: Prevalence rate of SBSy among school children ill with chronic sinusitis is 56%. Obstructive lung disease 
exacerbates earlier than non-obstructive following chronic sinusitis exacerbations 
16. The role of methylprednisolone in the treatment of pneumonia in school children 
S. PLJASKK KAMENOV, M. FILIPOVIC* AND B. KAMENOV** 
Health Center, “Institute of Pulmonary Diseases, **University Paediatric Hospital, Nis, Yugoslavia 
Aim: to establish the clinical usefulness of methylprednisolone treatment of severe pneumonia (SP) since the role of 
glucocorticoids in the management of pneumonia in school children remains controversial. 
Methods: the study included 35 cases of SP, that were admitted to our Health Center during the period February 1998 to 
February 1999. All the patients were treated with the second and third generation cephalosporin and erythromycin. One 
group of 20 patients (group A) was not treated with steroids, while the second group of 15 patients (group B) received 
1 mg/kg/day methylprednisolon. The groups were matched by age, sex, disease severity and clinical presentation. 
Results: no significant difference was noticed in: leukocyte count, percentage of lymphocytes, red blood cell sedimentation 
rate, hyperglycaemia, hypokalemia and renal dysfunction. Significantly better clinical improvement (reduced fever, chills, signs 
